v3.26.3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Net Investment from Medtronic
Accumulated Other Comprehensive Loss
Beginning balance at Apr. 28, 2023 $ 3,402 $ 0 $ 0 $ 0 $ 3,411 $ (9)
Beginning balance (shares) at Apr. 28, 2023   0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (107)       (107)  
Other comprehensive income (loss) (7)         (7)
Foreign exchange translation adjustment (7)          
Net transfers to from (to) Parent 160       160  
Ending balance (shares) at Apr. 26, 2024   0        
Ending balance at Apr. 26, 2024 3,448 $ 0 0 0 3,464 (16)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (198)       (198)  
Other comprehensive income (loss) 19         19
Foreign exchange translation adjustment 19          
Net transfers to from (to) Parent $ 62       62  
Ending balance (shares) at Apr. 25, 2025 0 0        
Ending balance at Apr. 25, 2025 $ 3,330 $ 0 0 0 3,328 3
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (16)       (16)  
Other comprehensive income (loss) 11         11
Foreign exchange translation adjustment 11          
Net transfers to from (to) Parent 212       212  
Ending balance at Jul. 25, 2025 3,537       3,524 13
Beginning balance at Apr. 25, 2025 $ 3,330 $ 0 0 0 3,328 3
Beginning balance (shares) at Apr. 25, 2025 0 0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss $ (317)     (116) (202)  
Other comprehensive income (loss) 20          
Foreign exchange translation adjustment 20         20
Pension and other postretirement benefit adjustments (13)         (13)
Distribution to Medtronic in connection with the Separation (229)   (229)      
Stock-based compensation expense 46   46      
Issuance of common stock in connection with the MiniMed IPO (in shares)   280,813,000        
Issuance of common stock in connection with the MiniMed IPO 538 $ 3 535      
Vesting of restricted stock units, net of shares withheld for taxes (in shares)   7,000        
Net transfers to from (to) Parent 238   (104)   363 (21)
Reclassification of Net Parent Investment from Medtronic $ 0   3,489   (3,489)  
Ending balance (shares) at Apr. 24, 2026 280,819,988 280,820,000        
Ending balance at Apr. 24, 2026 $ 3,611 $ 3 3,736 (116) $ 0 (12)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 0     0    
Foreign exchange translation adjustment (2)         (2)
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture 2   2      
Stock-based compensation expense 10   10      
Shares issued (in shares)   206,000        
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures $ (2)   (2)      
Vesting of restricted stock units, net of shares withheld for taxes (in shares)   180,000        
Ending balance (shares) at Jul. 31, 2026 281,205,548 281,206,000        
Ending balance at Jul. 31, 2026 $ 3,620 $ 3 $ 3,747 $ (116)   $ (14)